Nasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Buys 6,550 Shares

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman bought 6,550 shares of Nasus Pharma stock in a transaction on Wednesday, June 17th. The stock was acquired at an average cost of $3.10 per share, with a total value of $20,305.00. Following the acquisition, the chief executive officer owned 163,541 shares of the company’s stock, valued at $506,977.10. This trade represents a 4.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Dan Benjamin Teleman also recently made the following trade(s):

• On Wednesday, April 22nd, Dan Benjamin Teleman purchased 2,900 shares of Nasus Pharma stock. The shares were bought at an average cost of $3.76 per share, for a total transaction of $10,904.00.

Nasus Pharma Stock Up 1.6%

Shares of NSRX opened at $3.12 on Tuesday. The company has a 50-day moving average of $2.96. Nasus Pharma Ltd. has a 52-week low of $1.98 and a 52-week high of $9.99.

Wall Street Analysts Forecast Growth

Separately, Citizens Jmp reduced their price target on shares of Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. One analyst has rated the stock with a Buy rating, According to MarketBeat, Nasus Pharma presently has an average rating of “Buy” and a consensus target price of $18.00.

About Nasus Pharma

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.